NASDAQ:SURF - Surface Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.54 -0.05 (-0.58 %)
(As of 12/14/2018 04:50 AM ET)
Previous Close$8.59
Today's Range$8.30 - $8.69
52-Week Range$6.55 - $18.18
Volume133,200 shs
Average Volume202,758 shs
Market Capitalization$237.51 million
P/E RatioN/A
Dividend YieldN/A
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Current SymbolNASDAQ:SURF
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio6.44
Quick Ratio6.44


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.63 million
Price / Sales35.65
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-5.33%
Return on Assets-1.28%


Outstanding Shares27,680,000
Market Cap$237.51 million
OptionableNot Optionable

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) released its earnings results on Tuesday, November, 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06. The company had revenue of $1.73 million for the quarter, compared to analyst estimates of $2 million. View Surface Oncology's Earnings History.

What price target have analysts set for SURF?

4 equities research analysts have issued 1 year target prices for Surface Oncology's stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Surface Oncology's share price to reach $22.00 in the next year. This suggests a possible upside of 157.6% from the stock's current price. View Analyst Price Targets for Surface Oncology.

What is the consensus analysts' recommendation for Surface Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology.

Has Surface Oncology been receiving favorable news coverage?

Press coverage about SURF stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Surface Oncology earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days.

Are investors shorting Surface Oncology?

Surface Oncology saw a decrease in short interest in the month of November. As of November 30th, there was short interest totalling 438,778 shares, a decrease of 26.1% from the November 15th total of 594,105 shares. Based on an average trading volume of 248,803 shares, the days-to-cover ratio is currently 1.8 days. Currently, 4.5% of the shares of the stock are sold short. View Surface Oncology's Current Options Chain.

Who are some of Surface Oncology's key competitors?

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the folowing people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 60)
  • Mr. J. Jeffrey Goater, CEO, Pres, Sec. & Director (Age 43)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 55)
  • Dr. Scott C. Chappel, Chief Technology Officer (Age 67)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 44)

When did Surface Oncology IPO?

(SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

When did the company's lock-up period expire?

Surface Oncology's lock-up period expired on Tuesday, October 16th. Surface Oncology had issued 7,200,000 shares in its initial public offering on April 19th. The total size of the offering was $108,000,000 based on an initial share price of $15.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (8.21%), EcoR1 Capital LLC (4.94%), Citadel Advisors LLC (3.83%), BlackRock Inc. (2.18%), Victory Capital Management Inc. (1.95%) and Vanguard Group Inc. (1.59%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology.

Which major investors are selling Surface Oncology stock?

SURF stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc. and BlackRock Inc.. View Insider Buying and Selling for Surface Oncology.

Which major investors are buying Surface Oncology stock?

SURF stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Citadel Advisors LLC, Vanguard Group Inc, Vanguard Group Inc., Man Group plc, Marshall Wace North America L.P. and Strs Ohio. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $8.54.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $237.51 million and generates $6.63 million in revenue each year. Surface Oncology employs 56 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel